ABUS Logo

Arbutus Biopharma Corporation (ABUS) 

NASDAQ
Market Cap
$660.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
404 of 775
Rank in Industry
209 of 433

Largest Insider Buys in Sector

ABUS Stock Price History Chart

ABUS Stock Performance

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid …

Insider Activity of Arbutus Biopharma Corporation

Over the last 12 months, insiders at Arbutus Biopharma Corporation have bought $0 and sold $111,487 worth of Arbutus Biopharma Corporation stock.

On average, over the past 5 years, insiders at Arbutus Biopharma Corporation have bought $0 and sold $382,430 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,000 shares for transaction amount of $13,900 was made by HENRIQUES RICHARD C JR (director) on 2015‑08‑24.

List of Insider Buy and Sell Transactions, Arbutus Biopharma Corporation

2024-08-14Saledirector
8,846
0.0048%
$3.69$32,6370.00%
2024-02-02SaleInterim President & CEO
10,164
0.0057%
$2.31$23,504+34.03%
2024-02-02SaleChief Scientific Officer
9,982
0.0056%
$2.31$23,083+34.03%
2024-02-02SaleChief Financial Officer
9,593
0.0054%
$2.31$22,184+34.03%
2024-02-02SaleChief Medical Officer
4,358
0.0024%
$2.31$10,078+34.03%
2021-12-01SaleChief Scientific Officer
200,000
0.218%
$5.09$1.02M-44.14%
2021-02-09SaleChief Business Officer
20,000
0.0239%
$5.00$100,000-25.28%
2020-12-14SaleChief Business Officer
40,000
0.0439%
$5.00$200,032-29.51%
2020-07-23SaleChief Business Officer
20,000
0.0203%
$5.01$100,200-46.45%
2018-08-13SaleChief Scientific Officer
4,250
0.0076%
$9.51$40,436-60.00%
2018-07-11SaleChief Scientific Officer
10,000
0.017%
$10.00$100,000-61.98%
2018-07-09SaleChief Scientific Officer
10,000
0.0183%
$8.91$89,060-53.41%
2018-07-06SaleChief Scientific Officer
10,000
0.0166%
$8.45$84,500-55.27%
2018-07-05SaleChief Scientific Officer
10,000
0.0167%
$8.40$84,000-54.73%
2018-07-03SaleChief Scientific Officer
10,000
0.0174%
$8.00$80,000-50.24%
2017-10-03SaleChief Scientific Officer
20,000
0.0392%
$8.00$160,000-21.85%
2017-08-15SaleChief Scientific Officer
60,000
0.1079%
$3.70$222,000+51.33%
2015-08-24Purchasedirector
2,000
0.004%
$6.95$13,900-39.25%

Insider Historical Profitability

<0.0001%
HENRIQUES RICHARD C JRdirector
1000
0.0005%
$3.4910<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Whitefort Capital Management Lp$33.18M6.8212.86M-2.54%-$864,067.8021.68
BlackRock$26.84M5.5110.4M+0.14%+$36,943.02<0.01
Morgan Stanley$22.78M4.688.83M+26.43%+$4.76M<0.01
Kairos Capital Management Lp$20.23M4.167.84M-13.27%-$3.1M9.69
The Vanguard Group$15.45M3.175.99M-0.02%-$2,518.08<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.